Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01351415 · ClinicalTrials.gov registry record · Phase 3
A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
A Phase 3 study of Non-squamous Non-small Cell Lung Cancer, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 485
- Enrollment target
- 20
- Study locations
NCT01351415 is a Phase 3 study of Non-squamous Non-small Cell Lung Cancer that has completed, run by Hoffmann-La Roche. The registered enrollment target is 485 participants, above the 335-participant average among 7 other Non-squamous Non-small Cell Lung Cancer trials with a reported enrollment target (45% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT01351415, a Phase 3 study of Non-squamous Non-small Cell Lung Cancer, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 485 participants
- Enrollment target
- 20
- Study locations
Study Summary
This open-label, randomized, multicenter study will evaluate the efficacy and safety of bevacizumab (Avastin) in combination with standard of care (SOC) treatment in participants with advanced non-squamous NSCLC. Participants will be enrolled at documentation of progression of disease (PD) after 4-6 cycles of first-line treatment with bevacizumab plus a platinum doublet-containing therapy and a minimum of two cycles of bevacizumab maintenance treatment prior to PD. Participants will be randomly assigned to one of two treatment arms to receive either bevacizumab plus SOC treatment or SOC treatment alone.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Docetaxel
- DRUG Pemetrexed
- DRUG Erlotinib
Study Locations (20)
California
- East Valley Hematology ; Oncology Medical Group - Burbank
- California Cancer Associates for Research & Excellence, Inc. - Encinitas
- Scripps Clinic; Hematology & Oncology - La Jolla
- Sutter Cancer Center - Sacramento
- Coastal Integrative Cancer Care - San Luis Obispo
- Innovative Clinical Research Institute - Whittier
Florida
- Lynn Cancer Institute - West - Boca Raton
- Baptist - MD Anderson Cancer Center - Jacksonville
- Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy) - Jacksonville
- Mount Sinai Medical Center - Miami Beach
- Cancer Care Centers of Brevard - Rockledge
Arizona
- Palo Verde Hema/Onc - Glendale
- Arizona Center for Cancer Care - Glendale
Connecticut
- The Hospital of Central CT - New Britain
- Eastern Ct Hema/Onco Assoc; Dept of Oncology - Norwich
Georgia
- Emory Univ Winship Cancer Inst - Atlanta
- Summit Cancer Care PC - Savannah
Alabama
- USA Mitchell Cancer Institute - Mobile
Arkansas
- Clopton Clinic - Jonesboro
Idaho
- Kootenai Cancer Center - Post Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 485 participants |
| Start Date | 2011-06-25 |
| Est. Completion | 2016-06-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01351415
The ClinicalTrials.gov registry entry for NCT01351415 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 485 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 335-participant average among 7 other Non-squamous Non-small Cell Lung Cancer trials with a reported enrollment target (45% higher). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-squamous Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Bevacizumab is the first listed.
NCT01351415 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT01351415 about?
NCT01351415 is a clinical study titled "A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)". This open-label, randomized, multicenter study will evaluate the efficacy and safety of bevacizumab (Avastin) in combination with standard of care (SOC) treatment in participants with advanced non-squamous NSCLC. Participants will be enrolled at documentation of progression of disease (PD) after 4-6...
What is the current status of trial NCT01351415?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 485 participants. The study started on 2011-06-25. Estimated completion is 2016-06-25.
What conditions does trial NCT01351415 study?
This clinical trial studies the following conditions: Non-squamous Non-small Cell Lung Cancer.
What interventions are being tested in trial NCT01351415?
The interventions under investigation include: Bevacizumab (DRUG), Docetaxel (DRUG), Pemetrexed (DRUG), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT01351415?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01351415 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-squamous Non-small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
RECRUITING · Phase 3
-
Phase III Study of AK112 for NSCLC Patients
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation
COMPLETED · Phase 3
-
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 2
-
Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.